ReForm Biologics Announces the Appointment of Alan Herman, Ph.D. and Fred Larimore, Ph.D. to Scientific Advisory Board

WOBURN, Mass.–(BUSINESS WIRE)–ReForm
Biologics, a pharmaceutical technology company developing innovative
biologic formulations to improve drug delivery and manufacturing, today
announced the appointment of Alan Herman, Ph.D. and Fred Larimore, Ph.D.
to the company’s Scientific Advisory Board (SAB).

“Fred Larimore and Alan Herman together bring decades of experience in
the development and commercialization of biologics and biosimilars to
ReForm’s Scientific Advisory Board,” said John M. Sorvillo, PhD, Chief
Executive Officer, ReForm Biologics. “As Chief Scientific Officer at
Coherus Biosciences, Alan was leader in the company’s drive to create a
new model for developing safe, high-quality biosimilar therapeutics.
Fred’s experience in advising leading companies in process development,
commercialization, and manufacturing of biotech products will be
invaluable as ReForm expands our agreements with major pharmaceutical
and biotech companies to improve biologic formulations. On behalf of all
of us at ReForm, I welcome Alan and Fred to the SAB.”

“ReForm is using its unique technology and scientific expertise to
improve the formulation of biologics, which can lead to better
efficiency in manufacturing, improved product stability or alternative
dosing,” said Alan Herman. “I look forward to working with my fellow SAB
members as we help the ReForm team make biologics better.”

“ReForm has agreements with leading drug developers including Bayer AG,
Astellas and KBI Pharmaceuticals to improve the characteristics of
biologics for the ultimate benefit of patients,” said Fred Larimore. “I
am excited to be joining the ReForm Scientific Advisory Board to help
them achieve this important goal.”

Alan Herman is Principal at Alan Herman Consulting. He has over
35 years of experience in the life sciences sector, most recently as
Chief Scientific Officer at Coherus Biosciences. Previously, he was VP
of Product Development and CSO at Althea Technologies and President of
WindRose Analytica, Inc. He has a Ph.D. in Protein Chemistry from Duke
University.

Fred Larimore is Principal Consultant at Sierra Vista (SV)
Biotech Consulting with over 30 years experience in biotech development,
manufacturing, and technology transfer. Previously, he was VP of
Development at Cook Pharmica and a Research Fellow at Eli Lily & Co. He
obtained his Ph.D. in Biochemistry from the University of Minnesota –
Twin Cities.

About ReForm Biologics

ReForm Biologics has developed a technology platform that transforms the
formulation of biotherapeutics for the ultimate benefit of patients. Our
patented technology can extend product life-cycles, enable alternative
dosing, and improve manufacturing efficiency for our biopharmaceutical
partners. With multiple industry alliances to date, we offer formulation
development collaborations and product-specific licenses for a broad
spectrum of protein-based therapeutics.

We don’t make biologics — we make biologics better. www.reformbiologics.com

Contacts

Rob Kloppenburg
Shoreline Biotech Communications
(617) 930-5595